Article Text

Download PDFPDF
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
  1. Charlotte L Krieckaert1,
  2. Michael T Nurmohamed1,2,
  3. Gerrit Jan Wolbink1,3
  1. 1Department of Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, The Netherlands
  2. 2Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands
  3. 3Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands
  1. Correspondence to Dr Charlotte L Krieckaert, Jan van Breemen Research Institute | Reade, Reumatology, dr Jan van Breemenstraat 2, Amsterdam 1056 AB, The Netherlands; c.krieckaert{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Immunogenicity of adalimumab could impair important treatment outcome parameters in patients with rheumatoid arthritis (RA). Patients who developed antiadalimumab antibodies (AAA) during a 3 year time period achieved less often minimal disease activity or remission and treatment failure occurred more often compared with patients without AAA.1 There were remarkable baseline differences: patients developing AAA had more long-standing, severe disease and less often used concomitant medication including lower doses of methotrexate (MTX), compared with patients not developing AAA. In literature, a favourable effect of concomitant MTX use on the immunogenicity of adalimumab for several inflammatory conditions is suggested.2

To investigate which MTX dose is sufficient to reduce immunogenicity, patients of …

View Full Text


  • Funding Funding was provided by Abbott Laboratories and Pfizer. Abbott Laboratories and Pfizer had no involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication. In addition, this investigation was also facilitated by the Division of Research & Education of the Jan van Breemen Research Institute | Reade.

  • Competing interests CLK declares no competing interest. MTN has received consultancy fees from Abbott, Roche, Pfizer, Merk Sharp and Dohme (MSD), Union chimique belge (UCB), Swedisch orphan biovitrum (sobi) Bristol-Myers Squibb (BMS), payment for lectures from Abbott, Roche and Pfizer. GJW has received a research grant from Pfizer (Wyeth) (paid to the Institution) and payments for lectures from Pfizer and Amgen.

  • Ethics approval The study was approved by the medical ethics committee of Reade and Slotervaart Ziekenhuis.

  • Provenance and peer review Not commissioned; externally peer reviewed.